Gujarat Themis Biosyn AGM addendum: AoA change 2026

Addendum issued ahead of September 30 AGM

Gujarat Themis Biosyn has issued an addendum to the notice of its 45th Annual General Meeting (AGM) scheduled for September 30, 2026. The addendum seeks shareholder approval for a special resolution to amend Article 119 of the company’s Articles of Association (AoA). The proposed change is positioned as a response to how the legal and financing framework has evolved over time. In practical terms, the company is looking to make its borrowing and lender-related governance clauses more flexible. The addendum also outlines a mechanism for lender representation on the board without necessarily appointing nominee directors. The disclosures were made through filings to the exchange.

What Article 119 change is trying to achieve

The key proposed edit is the deletion of the phrase “(as such term is defined in the Act)” from the existing definition of a “Financial Institution” in Article 119. The company’s stated intent is to avoid being restricted to only those entities covered by a statutory definition. By removing this reference, Gujarat Themis Biosyn is seeking more room to borrow from lenders beyond traditional financial institutions. This matters because lending structures can include banks, funds, investors, and other credit providers that may not fall neatly into older definitional buckets. The company has also separately described “Financial Institution” broadly, supporting this intent. The proposal will require shareholder approval via a special resolution.

Broader definition of “Financial Institution” in the proposal

In the addendum, the company defines “Financial Institution” broadly. The definition includes investors, banks, funds, lending institutions, lenders, and other similar entities. This expanded framing aligns with the goal of enabling the company to access a wider set of borrowing arrangements. It also reflects how corporate credit markets have diversified, including private credit and structured instruments. The addendum’s approach indicates the company wants internal governance documents to keep pace with those changes. However, the final scope will depend on the resolution’s approval at the AGM.

Board observers instead of nominee directors

A notable feature of the addendum is the proposal to allow Financial Institutions to appoint an observer on the Board of Directors under specified conditions. This is distinct from appointing a nominee director. A board observer typically attends meetings and receives information but does not vote, depending on the agreed terms and the company’s governance structure. By enabling observers, the company appears to be offering a governance option that may be more workable for certain lenders. It can also reduce the need to formally reconstitute the board whenever a lender wants representation linked to funding. The addendum describes this observer right as conditional rather than automatic.

Conditions listed for appointing a board observer

The addendum lists specific conditions under which a Financial Institution may appoint a board observer. These include outstanding loans or debenture assistance granted by the institution. It also covers situations where the institution holds debentures through underwriting, direct subscription, or private placement. Another condition is the holding of shares through similar mechanisms. The addendum further includes outstanding liabilities that arise from guarantees furnished by the institution. Taken together, the conditions tie the observer right to meaningful financial exposure to the company.

Dividend record date and AGM schedule in filings

Separately, Gujarat Themis Biosyn has fixed September 23, 2026, as the record date to determine shareholder eligibility for its final dividend for FY26 (year ended March 31, 2026). The Board approved the record date in a filing dated September 18, 2026. The payout is stated to be subject to approval by members at the AGM scheduled for September 30, 2026. The company’s communications in the provided text refer to an addendum for the 45th AGM notice. The same set of details also contains a reference to a “56th Annual General Meeting (AGM)” for the dividend approval, alongside the September 30, 2026 date. Based on the information provided, the date is consistent, while the AGM numbering is presented differently across the text.

Capital-raising context: NCD meeting and QIP pricing

The corporate actions sit alongside other financing-related disclosures referenced in the provided material. Gujarat Themis Biosyn informed BSE that a board meeting was scheduled on September 10, 2026 to consider and approve raising funds via Non-Convertible Debentures (NCDs) through private placement. The company has also closed its qualified institutional placement (QIP), with an issue price fixed at ₹354 per equity share, as stated in the text. These developments provide context for why the company may want AoA provisions that are flexible across lender types and instruments. The addendum’s focus on broader lender definitions and observer rights aligns with a period where multiple funding channels are being referenced.

Stock snapshot and company background

The provided material includes market-price references around the period of disclosures. One data point shows ₹422.65, down ₹7.45 (1.73%) on a 1-day basis. Another reference shows a close price of ₹427 on September 18, and a “current price” around ₹427 to ₹427.40 in the same set of excerpts. These figures are presented as snapshots rather than a continuous price series. Gujarat Themis Biosyn was incorporated in 1981 and is described as manufacturing and selling finished active pharmaceutical ingredient (API) products using a fermentation process. The company is listed on BSE under scrip code 506879, as referenced in the addendum headline.

Key facts table

Why the change matters for governance and borrowing flexibility

From a governance standpoint, the change is designed to ensure the AoA does not constrain who qualifies as a “Financial Institution” for lending and related rights. Removing the statutory-definition reference can help the company deal with a wider set of entities providing credit or subscribing to instruments. The observer clause provides a structured way to accommodate lender oversight where exposure is significant, without always adding nominee directors to the board. This can matter for companies using multiple instruments such as debentures, private placements, or structured facilities. The proposal is framed as a flexibility measure rather than a one-off lender-specific action. Any changes will take effect only if shareholders approve the special resolution.

Conclusion

Gujarat Themis Biosyn’s AGM addendum is focused on updating Article 119 to reflect a broader lender universe and creating a defined pathway for board observers tied to financial exposure. Alongside the September 23 record date for the FY26 final dividend and the financing-related disclosures referenced in the text, the proposal signals an emphasis on adaptable capital-raising and lender engagement. The next step is shareholder voting at the AGM scheduled for September 30, 2026, as stated in the addendum notice.